We actively communicate on our business, services and technical capabilities. Use the resources on this page to browse through recent news, to subscribe to our news services or to meet us at one of our forthcoming events.
PolyPeptide achieves strong profitable growth in 2021
15 Mar 2022 - PolyPeptide Group AG (SIX: PPGN), a global leader in peptide custom development and manufacturing, today announced its results for the financial year 2021: Revenue growth of […]
Read moreGreen Chemistry Articles of Interest to the Pharmaceutical Industry
13 Mar 2022 - Bryan, M. C.; Dalton, C.; Díaz-Rodríguez, A.; Doerfler, J.; Engl, O. D.; Ferguson, P.; Molina, A. G.; Han, Z. S.; Hosford, J.; Howell, G. P.; Hutchby, M.; Li, W.; Munday, R. H.; Navarro, A.; Parmentier, M.; Pawlas, J.; Richardson, P. F.; Smith III, W. J.; Steven, A.; Takale, B. S.; Terrett, J. A.; Treitler, D. S.; Zeng, M. Org. Process Res. Dev. 2022, 26, 2, 251–262Publication Date: February 2, 2022 […]
Read moreEfficient and sustainable solutions for large scale peptide manufacturing
22 Dec 2021 - We are happy to share the latest scientific publication from the PolyPeptide Innovation Team, Dr. Renan Revetti Duran, Innovation Scientist and Dr. Olivier Ludemann-Hombourger, Global Director, […]
Read morePolyPeptide Group appoints Neil Thompson as Director Global Sales and Marketing and member of the Executive Committee, succeeding Jan Christensen
1 Dec 2021 - PolyPeptide Group AG, a global leader in peptide development and manufacturing, today announced the appointment of Neil Thompson as Director Global Sales and Marketing and member […]
Read moreResults of Accelerated Bookbuild Offering of 1,500,000 Existing Shares in PolyPeptide Group AG
10 Nov 2021 - PolyPeptide Group AG (“PolyPeptide”) has been informed that Draupnir Holding B.V. (“Draupnir”), which held 60.0% of PolyPeptide’s share capital as of close of trading on SIX […]
Read morePolyPeptide customer Cara Therapeutics with FDA approval for novel treatment of moderate-to-severe pruritus in hemodialysis patients
1 Sep 2021 - Long-term collaborative development process for peptide API successfully completed and continued with commercial supply agreement PolyPeptide is pleased to announce that its customer Cara Therapeutics (Nasdaq: […]
Read morePolyPeptide reports strong H1 2021 revenue growth and operating leverage amidst favorable market environment and encouraging business trends
17 Aug 2021 - PolyPeptide Group AG (SIX: PPGN), a global leader in peptide custom development and manufacturing, today announced its results for the first half of 2021: – Revenue […]
Read morePolyPeptide Group appoints Christina Del Vecchio as General Counsel and member of the Executive Committee
25 Jun 2021 - PolyPeptide Group AG, a global leader in peptide development and manufacturing, today announced the appointment of Christina Del Vecchio as General Counsel and member of the […]
Read moreProclamation honoring Jane Salik upon her retirement
11 May 2021 - The city of Torrance, California, honored Jane Salik for her investment in the Torrance community and her outstanding contributions to the Science and Peptide Industry. 05-11-21 […]
Read more